In patients with WT tumours on cetuximab both grade 0/1 and grade 2 + rash were associated with increased PFS ( HR 0.57 95 % CI 0.38-0 .86 ; p = 0.008 ; and HR 0.32 95 % CI 0.21-0 .49 ; p < 0.0001 ) respectively , in comparison with best supportive care ( BSC ) .